Literature DB >> 11559748

CHMP1 functions as a member of a newly defined family of vesicle trafficking proteins.

T L Howard1, D R Stauffer, C R Degnin, S M Hollenberg.   

Abstract

A multivesicular body is a vesicle-filled endosome that targets proteins to the interior of lysosomes. We have identified a conserved eukaryotic protein, human CHMP1, which is strongly implicated in multivesicular body formation. Immunocytochemistry and biochemical fractionation localize CHMP1 to early endosomes and CHMP1 physically interacts with SKD1/VPS4, a highly conserved protein directly linked to multivesicular body sorting in yeast. Similar to the action of a mutant SKD1 protein, overexpression of a fusion derivative of human CHMP1 dilates endosomal compartments and disrupts the normal distribution of several endosomal markers. Genetic studies in Saccharomyces cerevisiae further support a conserved role of CHMP1 in vesicle trafficking. Deletion of CHM1, the budding yeast homolog of CHMP1, results in defective sorting of carboxypeptidases S and Y and produces abnormal, multi-lamellar prevacuolar compartments. This phenotype classifies CHM1 as a member of the class E vacuolar protein sorting genes. Yeast Chm1p belongs to a structurally-related, but rather divergent family of proteins, including Vps24p and Snf7p and three novel proteins, Chm2p, Chm5p and Chm6p, which are all essential for multivesicular body sorting. These observations identify the conserved CHMP/Chmp family as a set of proteins fundamental to understanding multivesicular body sorting in eukaryotic organisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559748     DOI: 10.1242/jcs.114.13.2395

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  60 in total

1.  Identification and proteomic profiling of exosomes in human urine.

Authors:  Trairak Pisitkun; Rong-Fong Shen; Mark A Knepper
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 2.  Dynamics of ESCRT proteins.

Authors:  Nolwenn Jouvenet
Journal:  Cell Mol Life Sci       Date:  2012-06-06       Impact factor: 9.261

Review 3.  ESCRTs are everywhere.

Authors:  James H Hurley
Journal:  EMBO J       Date:  2015-08-25       Impact factor: 11.598

4.  Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding.

Authors:  Alessia Zamborlini; Yoshiko Usami; Sheli R Radoshitzky; Elena Popova; Giorgio Palu; Heinrich Göttlinger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

Review 5.  A Consensus View of ESCRT-Mediated Human Immunodeficiency Virus Type 1 Abscission.

Authors:  J Lippincott-Schwartz; E O Freed; S B van Engelenburg
Journal:  Annu Rev Virol       Date:  2017-07-17       Impact factor: 10.431

6.  Ist1 regulates Vps4 localization and assembly.

Authors:  Christian Dimaano; Charles B Jones; Abraham Hanono; Matt Curtiss; Markus Babst
Journal:  Mol Biol Cell       Date:  2007-11-21       Impact factor: 4.138

7.  Interaction maps of the Saccharomyces cerevisiae ESCRT-III protein Snf7.

Authors:  Barbara Sciskala; Ralf Kölling
Journal:  Eukaryot Cell       Date:  2013-09-20

8.  Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins.

Authors:  Juan Martin-Serrano; Anton Yarovoy; David Perez-Caballero; Paul D Bieniasz; Anton Yaravoy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

9.  RAP-1 and the RAL-1/exocyst pathway coordinate hypodermal cell organization in Caenorhabditis elegans.

Authors:  Ester W Frische; Wendy Pellis-van Berkel; Gijs van Haaften; Edwin Cuppen; Ronald H A Plasterk; Marcel Tijsterman; Johannes L Bos; Fried J T Zwartkruis
Journal:  EMBO J       Date:  2007-11-08       Impact factor: 11.598

10.  Novel interactions of ESCRT-III with LIP5 and VPS4 and their implications for ESCRT-III disassembly.

Authors:  Soomin Shim; Samuel A Merrill; Phyllis I Hanson
Journal:  Mol Biol Cell       Date:  2008-04-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.